whats'up

Induced pluripotent stem cells (IPSCs) hold great promise in regenerative medicine, personalized medicine and drug discovery. However, while avoiding the ethical controversies associated with embryonic stem cells, they carry neoplastic risk owing to the use of the oncogenes c-Myc and Lin28. This has limited their utility in the biomedical arena.

Work has previously demonstrated that IPSC generation can be uncoupled from c-Myc, but until now a viable oncogene- and virus-free method has proven elusive.

A new research article from Alan B Moy and colleagues at Cellular Engineering Technologies (IA, USA) and The John Paul II Medical Research Institute (IA, USA) describes a promising new IPSC reprogramming approach that attempts to solve these issues. The open access article, “Efficient method to create integration-free, virus-free, Myc and Lin28-free human induced pluripotent stem cells from adherent cells”, is available in Future Science OA.

Their approach saw adherent fibroblasts reprogrammed using a combination of reprogramming molecules and episomal vectors. The combinatorial approach was successful, yielding colonies in which 100% expressed SSEA4.

“Our reprogramming method provides patient- and disease-specific IPSC[s] for drug discovery and personalized medicine applications with lower risk of oncogenic perturbations due to Lin28 and Myc”, noted the authors. “The reprogramming method paves a pathway for autologous and allogeneic cell therapy that satisfies regulatory requirements.”

The team anticipates that virus- and oncogene-free IPSCs could advance cell therapies, diagnostics and personalized medicine. Furthermore, they envision the technology helping to reduce clinical trial failure rates and improve drug development.

 

 

 

Source : phys

Advancells

A-102, Sector-V Noida-201301, UP, India

Tel: +91-9654321400

Email: info@advancells.com 

 

 

Partner With Us

Newsletter Subscription

captcha

"Advancells is a strong advocate of greater transparency in medical procedures in general and Stem Cells Procedures in particular. As a part of our effort of bringing transparent procedures to our clients, we provide each client a Third Party Certificate (from an internationally accredited lab) for the cell count and viability of the cells that we are able to process from the autologous cell source of the patient. To view the sample copy of the certificate  "click here"

By Advancells. Copyright 2018. All Rights Reserved. All images and content used in this site are original. Any attempt to copy will come under criminal jurisdiction.